The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)

Administered By

Medicine, Endocrinology, Metabolism, and Nutrition

Awarded By

Eli Lilly and Company

Contributors

Rowell, Jennifer Voigt Principal Investigator

Start/End

September 1, 2020 - July 31, 2025